Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Role of Genomic Testing in mCRC

November 30th 2021

Experts in gastrointestinal cancers review the role of genomic testing in metastatic colorectal cancer and its impact on informing treatment decisions.

Overview of Colorectal Cancer

November 30th 2021

Tanios S. Bekaii-Saab, MD, Gerald Prager, MD, and Chiara Cremolini, MD, PhD, provide insight on the treatment landscape and international screening guidelines of colorectal cancer.

FDA Grants Fast Track Status to Arfolitixorin for Metastatic Colorectal Cancer

November 24th 2021

The FDA has granted a fast track designation to arfolitixorin as a potential therapeutic option for patients with metastatic colorectal cancer.

CTLA-4 Inhibitor AGEN1181 Shows Early Activity in Heavily Pretreated Advanced Solid Tumors

November 23rd 2021

AGEN1181, a next-generation CTLA-4 inhibitor, exhibited clinical activity both as a monotherapy and in combination with balstilimab in heavily pretreated patients with advanced solid tumors.

Dr. Ciombor on Anti-EGFR Therapy in Metastatic CRC

November 16th 2021

Kristen K. Ciombor, MD, MSCI, discusses the use of anti-EGFR therapy for the frontline treatment of patients with metastatic colorectal cancer.

Up-front Surgery, Biologics Do Not Improve Survival in Resectable CRC With Liver Metastases

November 11th 2021

Chemotherapy has demonstrated mixed findings in patients with resectable colorectal hepatic metastases, and long-term data suggest incorporating it into treatment algorithms have little impact on overall survival.

Nivolumab Plus Low-Dose Ipilimumab Provides Robust, Durable Clinical Benefit in Frontline MSI-H/dMMR mCRC

November 10th 2021

The combination of nivolumab and low-dose ipilimumab resulted in a deep and durable clinical benefit when used in the first-line treatment of patients with microsatellite instability–high and mismatch repair deficient metastatic colorectal cancer.

Targeted Therapies Make Major Strides in mCRC Management

November 7th 2021

The treatment algorithm in metastatic colorectal cancer has gone from accounting only for the sidedness of the primary tumor, performance status, volume of disease, and potential resectability to also include the genetics of the tumor, particularly for patients in need of second-line therapy.

Dr. Boland on Efforts Underway to Optimize the Utility of ctDNA in CRC

November 5th 2021

Patrick Boland, MD, discusses the utility of circulating tumor DNA in patients with metastatic colorectal cancer.

Dr. Hubbard on MRD Assessment to Inform Treatment Decisions in Resected Metastatic CRC

November 2nd 2021

Joleen M. Hubbard, MD, discusses minimal residual disease assessment to inform treatment decisions in patients with resected metastatic colorectal cancer.

Jain and Spaggiari Speak to Surgical and Systemic Considerations for CRC Liver Metastases

October 28th 2021

Dr. Jain and Dr. Spaggiari highlight key advancements in the treatment of patients with colorectal cancer liver metastases, patient and disease factors to consider during surgical and systemic treatment decisions, and the importance of multidisciplinary care in this patient population.

FORTE Trial Set to Examine Optimal Colonoscopy Frequency for CRC Prevention

October 27th 2021

The randomized FORTE/NRG-CC005 trial, which is evaluating the frequency of surveillance colonoscopy in individuals with a first-time presentation and removal of 1 to 2 small, benign polyps, has been launched.

TAS-102 Plus Bevacizumab Misses PFS End Point in Frontline Unresectable Metastatic CRC

October 22nd 2021

The frontline combination of trifluridine/tipiracil and bevacizumab was not found to result in a significant improvement in progression-free survival over capecitabine and bevacizumab in patients with unresectable metastatic colorectal cancer who are not eligible to receive intensive therapy, missing the primary end point of the phase 3 SOLSTICE trial.

Dr. Weiss on the Rationale for the KRYSTAL-1 Trial in KRAS G12C–Mutated CRC

October 19th 2021

Jared Weiss, MD, discusses the rationale for the phase 1/2 KRYSTAL-1 trial in patients with KRAS G12C–mutated colorectal cancer.

Dr. Mulcahy on Key Takeaways from the EPOCH Trial With TheraSphere Y-90 in CRC

October 15th 2021

Mary F. Mulcahy, MD, discusses the key takeaways from the ongoing EPOCH trial in patients with colorectal cancer and liver metastases.

Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial

October 15th 2021

Expert Riad Salem, MD, MBA, highlights key data from the phase 3 EPOCH study, which evaluated TheraSphere in patients with mCRC and liver metastases who failed first line chemotherapy.

New Surgical and Systemic Approaches Enable Earlier Intervention in CRC With Liver Metastases

October 8th 2021

Shikha Jain, MD, FACP, and Mario Spaggiari, MD, highlight key advancements made in the treatment of patients with colorectal cancer and liver metastases, patient and disease factors to consider for surgical and systemic treatment, and the importance of multidisciplinary care for this population.

Dr. Spaggiari on Surgical Interventions in CRC With Liver Metastases

October 7th 2021

Mario Spaggiari, MD, discusses surgical interventions in colorectal cancer with liver metastases.

Dr. Jain on Advances With Surgery and Systemic Therapy in CRC With Liver Metastases

October 7th 2021

Shikha Jain, MD, FACP, discusses advances with surgical interventions and systemic therapies in colorectal cancer with liver metastases.

MSH3 IHC and Tetranucleotide MSI Analysis Should Not Be Routine in CRC

October 7th 2021

MSH3 immunohistochemistry and tetranucleotide analysis failed to demonstrate concordance in identifying microsatellite instability in a cohort of colorectal cancer cases at selected tetranucleotide repeats, suggesting that the dual assessment strategy is not ready for routine use in diagnostic workup.